ATE353654T1 - Behandlung der diabetes mit thiazolidindione und sulphonylurea - Google Patents

Behandlung der diabetes mit thiazolidindione und sulphonylurea

Info

Publication number
ATE353654T1
ATE353654T1 AT98936363T AT98936363T ATE353654T1 AT E353654 T1 ATE353654 T1 AT E353654T1 AT 98936363 T AT98936363 T AT 98936363T AT 98936363 T AT98936363 T AT 98936363T AT E353654 T1 ATE353654 T1 AT E353654T1
Authority
AT
Austria
Prior art keywords
thiazolidindione
sulphonylurea
diabetes
treatment
Prior art date
Application number
AT98936363T
Other languages
German (de)
English (en)
Inventor
Stephen Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE353654(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712854.0A external-priority patent/GB9712854D0/en
Priority claimed from GBGB9806710.1A external-priority patent/GB9806710D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE353654T1 publication Critical patent/ATE353654T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98936363T 1997-06-18 1998-06-15 Behandlung der diabetes mit thiazolidindione und sulphonylurea ATE353654T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712854.0A GB9712854D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806710.1A GB9806710D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
ATE353654T1 true ATE353654T1 (de) 2007-03-15

Family

ID=26311744

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98936363T ATE353654T1 (de) 1997-06-18 1998-06-15 Behandlung der diabetes mit thiazolidindione und sulphonylurea

Country Status (34)

Country Link
EP (3) EP2266576A1 (US06559137-20030506-C00071.png)
JP (1) JP2001523270A (US06559137-20030506-C00071.png)
KR (3) KR20070011651A (US06559137-20030506-C00071.png)
CN (1) CN1168451C (US06559137-20030506-C00071.png)
AP (1) AP1600A (US06559137-20030506-C00071.png)
AR (2) AR008025A1 (US06559137-20030506-C00071.png)
AT (1) ATE353654T1 (US06559137-20030506-C00071.png)
AU (1) AU8539298A (US06559137-20030506-C00071.png)
BG (2) BG64817B1 (US06559137-20030506-C00071.png)
BR (1) BR9810142A (US06559137-20030506-C00071.png)
CA (1) CA2294385C (US06559137-20030506-C00071.png)
CO (1) CO4940457A1 (US06559137-20030506-C00071.png)
CZ (1) CZ299310B6 (US06559137-20030506-C00071.png)
DE (1) DE69837089T2 (US06559137-20030506-C00071.png)
DZ (1) DZ2522A1 (US06559137-20030506-C00071.png)
EA (1) EA003025B1 (US06559137-20030506-C00071.png)
ES (1) ES2283064T3 (US06559137-20030506-C00071.png)
HK (1) HK1028200A1 (US06559137-20030506-C00071.png)
ID (1) ID24065A (US06559137-20030506-C00071.png)
IL (1) IL133137A (US06559137-20030506-C00071.png)
IN (1) IN189319B (US06559137-20030506-C00071.png)
MA (1) MA24571A1 (US06559137-20030506-C00071.png)
MY (1) MY125855A (US06559137-20030506-C00071.png)
NO (3) NO326263B1 (US06559137-20030506-C00071.png)
NZ (1) NZ501163A (US06559137-20030506-C00071.png)
OA (1) OA11510A (US06559137-20030506-C00071.png)
PE (1) PE108199A1 (US06559137-20030506-C00071.png)
PL (2) PL337510A1 (US06559137-20030506-C00071.png)
SK (1) SK286028B6 (US06559137-20030506-C00071.png)
TR (1) TR199903096T2 (US06559137-20030506-C00071.png)
TW (1) TW542717B (US06559137-20030506-C00071.png)
UA (1) UA67743C2 (US06559137-20030506-C00071.png)
UY (1) UY25048A1 (US06559137-20030506-C00071.png)
WO (1) WO1998057649A1 (US06559137-20030506-C00071.png)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
DK1284268T3 (da) 1999-04-23 2008-04-28 Smithkline Beecham Plc Fremstilling af en polymorf form af et thiazolidindionderivat
CA2389237A1 (en) 1999-11-01 2001-05-10 Wisconsin Alumni Research Foundation Abc1 modulation for the modulation of cholesterol transport
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
KR100698595B1 (ko) * 2003-09-29 2007-03-21 보령제약 주식회사 무정형 또는 준결정형 글리메피리드, 이의 제조방법 및 무정형 또는 준결정형 글리메피리드를 포함하는 약학적조성물
CA2540225C (en) 2003-10-31 2012-03-06 Takeda Pharmaceutical Company Limited Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
KR20080080126A (ko) 2005-12-22 2008-09-02 다케다 야쿠힌 고교 가부시키가이샤 인슐린 감작제를 함유하는 고체 제제
CN104158867B (zh) * 2014-08-06 2017-05-17 电子科技大学 一种基于wave协议的信息多跳转发方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物,其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
EP0306228B1 (en) * 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008651A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5061717A (en) 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
CA2086606A1 (en) 1990-07-03 1992-01-04 Kunihiro Niigata Bisheterocyclic compound
CA2087437A1 (en) 1990-08-23 1992-02-24 Steven W. Goldstein Hypoglycemic hydroxyurea derivatives
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−2,4−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
HUT68370A (en) 1991-04-11 1995-06-28 Takeda Chemical Industries Ltd Thiazolidine derivatives, pharmaceutical compositions containing them and process for their production
TW222626B (US06559137-20030506-C00071.png) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE69219136T2 (de) * 1991-08-26 1997-08-28 Upjohn Co Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
JPH07505647A (ja) 1992-04-10 1995-06-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 複素環化合物および2型糖尿病の治療におけるそれらの使用
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
DE69331010D1 (de) 1992-07-03 2001-11-29 Smithkline Beecham Plc Benzoxazol- und benzothiazol-derivate als arzneimittel
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
BG104058A (en) 2000-10-31
CZ9904577A3 (en) 2001-05-16
CN1260719A (zh) 2000-07-19
CZ299310B6 (cs) 2008-06-18
ES2283064T3 (es) 2007-10-16
HK1028200A1 (en) 2001-02-09
NO326263B1 (no) 2008-10-27
AR012996A1 (es) 2000-11-22
AP9901717A0 (en) 1999-12-31
UY25048A1 (es) 2000-09-29
CA2294385A1 (en) 1998-12-23
TW542717B (en) 2003-07-21
KR20010013840A (ko) 2001-02-26
JP2001523270A (ja) 2001-11-20
PL337510A1 (en) 2000-08-28
IN189319B (US06559137-20030506-C00071.png) 2003-02-08
TR199903096T2 (xx) 2000-08-21
EP0999845A1 (en) 2000-05-17
NO2009002I1 (no) 2009-03-02
IL133137A (en) 2004-02-08
DE69837089T2 (de) 2007-06-21
NO996264L (no) 2000-02-17
OA11510A (en) 2004-02-03
BR9810142A (pt) 2000-08-08
DE69837089D1 (de) 2007-03-29
BG64817B1 (bg) 2006-05-31
AU8539298A (en) 1999-01-04
SK286028B6 (sk) 2008-01-07
CO4940457A1 (es) 2000-07-24
MA24571A1 (fr) 1998-12-31
BG109397A (bg) 2006-05-31
NZ501163A (en) 2002-02-01
EA003025B1 (ru) 2002-12-26
EP1671637A3 (en) 2007-12-19
KR20070011651A (ko) 2007-01-24
NO20083276L (no) 2000-02-17
WO1998057649A1 (en) 1998-12-23
EP1671637A2 (en) 2006-06-21
MY125855A (en) 2006-08-30
CA2294385C (en) 2007-06-05
CN1168451C (zh) 2004-09-29
IL133137A0 (en) 2001-03-19
PE108199A1 (es) 2000-01-14
EP0999845B1 (en) 2007-02-14
DZ2522A1 (fr) 2003-02-01
PL198018B1 (pl) 2008-05-30
AP1600A (en) 2006-04-28
SK179199A3 (en) 2000-11-07
NO996264D0 (no) 1999-12-17
EP2266576A1 (en) 2010-12-29
KR20080011356A (ko) 2008-02-01
ID24065A (id) 2000-07-06
EA200000039A1 (ru) 2000-08-28
AR008025A1 (es) 1999-12-09
UA67743C2 (uk) 2004-07-15

Similar Documents

Publication Publication Date Title
ATE355840T1 (de) Behandlung der diabetes mit thiazolidindione und metformin
DE69817446D1 (de) Behandlung von diabetes
EE9900345A (et) Sulfonüülkarbamiidi ja glitasooni sünergistilised kombinatsioonid diabeedi raviks
FI970357A (fi) Tyypin II diabeteksen hoitoon käyttökelpoisia bensoksatsoli- ja pyridiinijohdannaisia
DE69836008D1 (de) Zusammensetzung und behandlungsmittel
DE69829763D1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
FI965204A (fi) Bromelaiinin lääkekäyttö
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
DE69838066D1 (de) Behandlung der diabetes mit thiazolidindione und sulphonylurea
DE69837089D1 (de) Behandlung der diabetes mit thiazolidindione und sulphonylurea
PL337577A1 (en) Treatment of diabetes with thiazolydinone and alpha - glucosidaze inhibitor
DE69705328D1 (de) Organischer photogeleiter und dessen behandlung
FI963263A (fi) Bromelaiinin lääkinnällinen käyttö
DE69713442D1 (de) Thioürazil-Derivate und diese enthaltende Metall-Oberflächebehandlungsmittel
ATE432709T1 (de) Behandlung von diabetes
ID24439A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
ID17459A (id) Unsur-unsur pengobatan
ID24521A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
UA25095A (uk) Ліhімеhт для лікуваhhя каhдидозhого і змішаhого вульвовагіhіту
LV12070A (lv) Ierice rokas zaga zobu asinasanai
GB9700667D0 (en) Materials and methods relating to the treatment of biofilms
KR960000384U (ko) 볶음기의 잔유처리 구조

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties